RENISHAW NEURO SOLUTIONS LTD

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +17.6%

  £2,167,881 → £2,549,758

• Cash

  -28.1%

  £180,300 → £129,595

• Net assets

  -54.6%

  -£10,726,807 → -£16,579,730

• Employees

  -6.4%

  47 → 44

• Operating profit

  -9.6%

  -£6,165,530 → -£6,757,441

• Profit before tax

  -14.4%

  -£6,814,938 → -£7,796,731

• Wages

  +13%

  £2,454,149 → £2,773,503

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. RENISHAW NEURO SOLUTIONS LTD 2016-12-13 → present
2. HOP TO BUSINESS LIMITED 2016-09-14 → 2016-12-13

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In preparing these financial statements, the Directors have adopted the going concern basis. The Company's parent undertaking, Renishaw plc, has provided a letter of support in meeting financial obligations for a period to 31 May 2026.”

Group structure

1. RENISHAW NEURO SOLUTIONS LTD · parent
   1. Renishaw Mayfield Sarl 100% · France · neurosurgery business

Significant events

• “On 27 February 2025 Renishaw plc, the ultimate parent, announced it would enter a consultation period over the proposal to close the drug delivery aspect of Renishaw Neuro Solutions Limited.”
• “On 01 April 2025, following the consultation period, it was announced that Renishaw plc will move forward with its proposal to close the drug delivery aspect of the Company. The closure is expected to take place by the end of 30 June 2025.”
• “Due to the proposal, the company has recognised a full impairment of £2,020,342 against intangible assets as the assets relate to drug delivery. An impairment of £29,312 has been recognised against tangible fixed assets, and the stock has been written down to its net realisable value, with a charge of £230,974 recognised.”
• “An additional c.£1,000,000 is expected to be incurred related to the closure of Drug Delivery.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

0

last 24 months

Officers appointed

3

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.